Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
222 studies found for:    "polycythemia vera"
Show Display Options
RSS Create an RSS feed from your search for:
"polycythemia vera"
Need help? See RSS Feeds
Choose a feed type:
Show studies first received on any dateShow studies that were first received in the last 14 days
Show studies last updated date on any dateShow studies that were added or modified in the last 14 days
Rank Status Study
1 Completed Dasatinib in Polycythemia Vera
Condition: Polycythemia Vera
Intervention: Drug: Dasatinib
2 Terminated A Phase 1 Study of XL019 in Adults With Polycythemia Vera
Condition: Polycythemia Vera
Intervention: Drug: XL019
3 Completed
Has Results
Randomized Switch Study From Hydroxyurea to Ruxolitinib for RELIEF of Polycythemia Vera Symptoms: The Relief Study
Condition: Polycythemia Vera
Interventions: Drug: Ruxolitinib;   Drug: Hydroxyurea (HU);   Drug: HU-placebo;   Drug: Ruxolitinib-placebo
4 Completed Efficacy and Safety of Pegylated Interferon Alfa in Polycythemia Vera
Condition: Polycythemia Vera
Intervention: Drug: pegylated interferon-alfa 2a
5 Completed Phase II Study of GIVINOSTAT (ITF2357) in Combination With Hydroxyurea in Polycythemia Vera
Condition: Polycythemia Vera
Interventions: Drug: GIVINOSTAT (ITF2357) 50 mg o.d. + MTD Hydroxyurea;   Drug: GIVINOSTAT (ITF2357) 50 mg b.i.d. + MTD Hydroxyurea
6 Not yet recruiting Incidence of Iron Deficiency in Polycythemia Vera (PV) and Association With Disease Features
Condition: Polycythemia Vera
Intervention: Other: questionnaires
7 Recruiting A Two-part Study to Assess the Safety and Preliminary Efficacy of Givinostat in Patients With Polycythemia Vera
Condition: Polycythemia Vera
Intervention: Drug: Givinostat
8 Completed Treatment of Polycythemia Vera With Gleevec
Condition: Polycythemia Vera
Intervention: Drug: Gleevec
9 Recruiting Expanded Treatment Protocol (ETP) of Ruxolitinib in Patients With Polycythemia Vera Who Are Hydroxyurea Resistant or Intolerant and for Whom no Treatment Alternatives Are Available.
Condition: Polycythemia Vera
Intervention: Drug: Ruxolitinib
10 Active, not recruiting Prospective Observational Study Of Patients With Polycythemia Vera In US Clinical Practices (REVEAL)
Condition: Polycythemia Vera
Intervention:
11 Completed Study to Assess the Self-administration of AOP2014 Using a Pen, Developed for the Treatment of Polycythemia Vera Patients
Condition: Polycythemia Vera
Intervention: Drug: Pegylated-Proline-Interferon alpha-2b in a Pre-filled Pen
12 Completed Effects of Imatinib Mesylate in Polycythemia Vera
Condition: Polycythemia Vera
Intervention: Drug: Imatinib Mesylate
13 Active, not recruiting AOP2014 vs. BAT in Patients With Polycythemia Vera Who Previously Participated in the PROUD-PV Study.
Condition: Polycythemia Vera
Interventions: Drug: Pegylated-Proline-interferon alpha-2b;   Drug: Best available therapy (BAT)
14 Active, not recruiting Ruxolitinib Efficacy and Safety in Patients With HU Resistant or Intolerant Polycythemia Vera vs Best Available Therapy.
Condition: Polycythemia Vera
Interventions: Drug: Best Available Therapy;   Drug: ruxolitinib
15 Terminated Trial of Erlotinib in Patients With JAK-2 V617F Positive Polycythemia Vera
Condition: Polycythemia Vera
Intervention: Drug: Erlotinib
16 Completed Pegylated Interferon Alpha-2b Versus Hydroxyurea in Polycythemia Vera
Condition: Polycythemia Vera
Interventions: Drug: Peg-P-IFN-alpha-2b (AOP2014);   Drug: Hydroxyurea
17 Terminated Large-scale Trial Testing the Intensity of CYTOreductive Therapy in Polycythemia Vera (PV)
Condition: Polycythemia Vera
Interventions: Drug: Hydroxyurea;   Procedure: Phlebotomy
18 Active, not recruiting Safety Study of Pegylated Interferon Alpha 2b to Treat Polycythemia Vera
Condition: Polycythemia Vera
Intervention: Drug: PEG-P-INF alpha-2b (P1101)
19 Withdrawn Clopidogrel and Aspirin for the Treatment of Polycythemia Vera
Condition: Polycythemia Vera
Interventions: Drug: Clopidogrel (Plavix);   Drug: Placebo;   Drug: Aspirin
20 Active, not recruiting
Has Results
Study of Efficacy and Safety in Polycythemia Vera Subjects Who Are Resistant to or Intolerant of Hydroxyurea: JAK Inhibitor INC424 (INCB018424) Tablets Versus Best Available Care: (The RESPONSE Trial)
Condition: Polycythemia Vera
Interventions: Drug: ruxolitinib tablets;   Other: Best Available Therapy (BAT)

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.